No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

IZI Medical Products Announces the Launch of Vertefix® HV Cement with Insite™ Tracking Beads

Editor: What To Know

  • It has an optimal volume of cement with good working time and viscosity, along with great visualization so you can see when the cement is flowing and where it is going.
  • The new Vertefix HV Cement with Insite tracking beads offers high viscosity and long working time and is an innovative enhancement to IZI’s vertebral augmentation portfolio.
  • “Our goal in developing Vertefix HV was to give physicians a better way to track and control where cement is flowing during their procedures,”.

IZI Medical Products, LLC (“IZI”), a leading manufacturer of interventional radiology devices and products to treat vertebral compression fractures, announces the official launch of Vertefix HV Cement (“Vertefix HV”).

Vertefix HV provides a unique solution that addresses the need for real-time flow visualization during cement injection for vertebroplasty and kyphoplasty procedures.

“Our goal in developing Vertefix HV was to give physicians a better way to track and control where cement is flowing during their procedures,” said Greg Groenke, CEO, IZI Medical Products. “The introduction of variable-sized barium particles with high viscosity makes this possible, improving outcomes and safety for patients.”

“Vertefix HV will help you control your cement and allow you to have excellent cement viscosity immediately after mixing. It has an optimal volume of cement with good working time and viscosity, along with great visualization so you can see when the cement is flowing and where it is going. The Insite beads are a great addition and now novel to all of the cements on the market. Bottom line is it’s the best cement I’ve used since I can remember,” said Dr. Douglas Beall, Chief of Services and Interventional Spine Services, Comprehensive Specialty Care, Edmond, Oklahoma.

“Improved visualization of cement has always been one of the goals to provide better safety with kyphoplasty and vertebroplasty. If you can visualize the cement better it makes the procedure safer, so the improved visualization by having variable-size barium particles is really nice,” said Dr. Jonathan Morris, Neuroradiologist.

The new Vertefix HV Cement with Insite tracking beads offers high viscosity and long working time and is an innovative enhancement to IZI’s vertebral augmentation portfolio. “We worked with physicians to find out what would really help them in vertebral augmentation procedures. Their input was insightful, and we’re pleased with what we’ve been able to deliver with Vertefix HV,” said Jovie Soriano, SVP Marketing and Business Development, IZI Medical Products.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy